OP-1250 Plus Palbociclib Demonstrates Activity, Safety in HR+/HER2– Metastatic Breast Cancer
The combination of OP-1250 and palbociclib produced a tolerable safety profile and elicited tumor responses and disease stabilization in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
United States Western Australia Marlene Chan Breast Cancer Annual Congress Cancer Annual Hollywood Private Hospital
Source: onclive.com